health
Hosted by MDS Foundation · health · EN
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research. The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
26%
Guest openness
Selective
Sign up to generate a grounded pitch for MDS Professional Report.
Signup to Generate a PitchThis podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research. The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
MDS Professional Report is hosted by MDS Foundation. The show has published 13 episodes to date.
Recent episodes include "EHA 2025 updates [MDS Professional Report]" (23 September 2025, 23 minutes), "Pathogenesis and inflammaging in MDS [MDS Professional Report]" (1 February 2025, 29 minutes), and "Treatment of lower-risk MDS [MDS Professional Report]" (15 December 2024, 29 minutes).
MDS Professional Report publishes roughly irregularly, with episodes averaging 27 minutes across 13 episodes.
Booking probability for MDS Professional Report is 26%, and the host is rated Selective on guests. MDS Professional Report requires a Pod Score of 80 or higher. MDS Professional Report's contact route on record: verified email.
The strongest fits for MDS Professional Report are Health & Wellness Services. MDS Professional Report has a health audience.
MDS Foundation hosts MDS Professional Report, a health podcast with 13 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
MDS Professional Report
This episode features Dr. Nikolaos Papadantonakis from the Winship Cancer Institute of Emory University and Dr. Amer Zeidan from the Yale School of Medicine, discussing research on Myelodysplastic Syndromes (MDS)...
Dr. Moshe Mittelman is hosting the world-leading expert Dr. Michael Savona and they have an attractive conversation on several mechanisms involved in the pathogenesis of MDS, including the interaction between genetics...
Prof. Uwe Platzbecker from Leipzig and Prof. Moshe Mittelman from Tel-Aviv in an interesting conversation on the various available therapeutic modalities for patients with lower-risk MDS.
Prof. Nicolaus Kröger from Hamburg and Prof. Moshe Mittelman from Tel-Aviv, in a stimulating conversation on the various therapeutic modalities, including hematopoietic transplantation, in patients with higher-risk MDS.
Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with a special focus on Higher-risk MDs, and providing their take home messages.
Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (ASH) 2023 meeting. They provide some data on luspatercept...
Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss issues related to RBC transfusions, the hemoglobin threshold for transfusion and related quality of life issues.
Prof. Akiko Shimamura of Harvard Medical School, Boston, a world known expert of pediatric hematology discusses with Prof. Guillermo Sanz ,of Valencia and Prof. Moshe Mittelman, of Tel Aviv, the various aspects of bone...
Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, follow up and prediction of treatment. They also discuss the role of the newly...
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit<br />Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,<br />discuss several important presentations from the recent...
Chien Aza – Pembro - BJH<br />The combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk MDS and may lead to the introduction of an important class of medications...
We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk myelodysplastic syndromes.We will then report a study testing the efficacy and...
PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsDescription:⦁ About a third...
Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53. That is: not all of them are infeed associated with poor prognosis.<br...
Recent guests on MDS Professional Report. Study who booked and why before you pitch.
Yale School of Medicine
Winship Cancer Institute of Emory University
The Tel Aviv Sourasky Medical Center
Leipzig
PitchCentric classifies MDS Professional Report under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
